Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

TON - April 2019, Vol 12, No 2

San Diego, CA—For children and young adults diagnosed with acute lymphoblastic leukemia (ALL), receiving treatment at specialized cancer centers has been associated with improved outcomes versus nonspecialized centers, but this comes at an increased cost, according to data presented at ASH 2018.
San Diego, CA—A dizzying array of new chimeric antigen receptor (CAR) T-cell therapies targeting the B-cell maturation antigen (BCMA) designed specifically for the treatment of multiple myeloma was presented at ASH 2018. BCMA-targeted CAR T-cell therapies are designed to improve T-cell persistence, depth of response, and tolerability. Response rates reported at ASH 2018 range from 70% to 100%, depending on the patient population and the use of previous regimens.
The Cedars-Sinai Blood & Marrow Transplant Program, Los Angeles, CA, has performed more than 2200 stem-cell and bone marrow transplants since its inception in 1990. The program is accredited for autologous and allogeneic transplant by the Foundation for the Accreditation of Cellular Therapy and is a National Marrow Donor Program/Be The Match Transplant Center. It has also been recognized as a Blue Cross Center of Medical Excellence, a designation awarded to select hospitals that meet evidence-based standards and provide high-quality care for patients.
Currently, there are limited therapies to prevent or delay recurrence in advanced ovarian cancer, with approximately 70% of patients having a recurrence within 3 years. The effectiveness of olaparib, an oral poly (ADP-ribose) polymerase inhibitor, in relapsed disease has been well-established; however, its benefit as a maintenance therapy in newly diagnosed advanced ovarian cancer is uncertain.
Page 2 of 2
Results 11 - 14 of 14